

**DIFFERENTIATION OF *BLASTOCYSTIS* SUBTYPES AND THEIR
ASSOCIATION WITH GUT MICROBIOTA IN TYPE 2 DIABETES MELLITUS
PATIENTS AND NON-DIABETIC INDIVIDUALS**

Nurul Saadah binti Mohd Shaari

Thesis submitted in partial fulfilment for the degree of
MASTER OF MEDICAL SCIENCE

UNIVERSITI SAINS ISLAM MALAYSIA

September 2024

ACKNOWLEDGEMENTS

Alhamdulillah Rabbil 'Alamiin, all praises are to Allah SWT as the lord of the worlds who has given the health and strength to me in completing this thesis. May Allah's peace and blessing be upon His final prophet and messenger, Muhammad SAW, his family, and his companions.

This thesis would not possible to be completed without the guidance and help from several individuals who in one way or another contributed and extended their valuable assistance in the preparation and completion of this study, it is pleasure to thanks those who's made it possible.

First and foremost, my deepest gratitude goes to my supervisor, Dr. Noradilah Samseh Abdullah, for her continuous guidance and expertise throughout this research journey. I also extend my appreciation to all internal and external co-supervisors especially Dr Rahman Omar, Dr. Wan Shahida and Dr. Nadeeya Ayn for their assistance during sample collection and their insights into this study. Thanks to dean of FPSK, head of programme and USIM staffs for cooperation during this study.

I must acknowledge the support of Aishah, my research colleague, for her assistance in sample collection. But most importantly, I want to express my deep gratitude to my postgraduate family, including Syida, Syafiqah, Ain, Nuha, Intan, Ad, and others, for their collaboration, insightful discussions, and unwavering support. Your companionship has made my postgraduate journey incredibly enriching and enjoyable.

A special mention goes to my family, especially my mother, [REDACTED], whose prayers, encouragement, and comforting presence were my pillars during challenging times. I dedicate this work to my beloved late father, Mohd Shaari bin Said, whose memory and inspiration will forever motivate me. I also want to thank my in-laws, Ibu and Abah for their understanding and support. I extend my appreciation to my siblings for their ongoing support and motivation since I decided to take this path.

To my dear friends, Elyani, Ada, Kak Aisyah, and others who accompanied me on this journey, your friendship, encouragement, and understanding have been invaluable. I would like to extend my gratitude to Madam Adlin for her support, delicious meals, and for being a part of my home in Nilai. I was blessed to meet you.

And the most important source of strength is my wonderful husband [REDACTED] for his constant support, encouragement, and belief in me. His love and understanding kept me motivated and focused throughout this journey. I am grateful for his unwavering presence and belief in my abilities. Thank you for always being there for me. Lastly, I'm grateful to myself for persevering and staying resilient throughout this journey. There were moments when I needed to acknowledge and address certain emotions because of this study. Thank you for not giving up!

ABSTRAK

Pengaruh anaerob protozoa usus *Blastocystis* terhadap kesihatan usus manusia masih kurang difahami, terutamanya dalam Diabetes Mellitus Jenis II (T2DM). Prevalens yang tinggi dalam jangkitan *Blastocystis* telah dilaporkan dalam pesakit T2DM, yang mana mencadangkan satu potensi terhadap hubungan dengan microbiota usus. Walaubagaimanapun, hubungan ini tidak didokumentasikan dengan baik dalam setting klinikal. Oleh itu, satu kajian keratan rentas telah dijalankan yang melibatkan 203 peserta, termasuk pesakit T2DM dan individu yang tidak menghidap diabetes (bukan-DM), untuk menilai prevalens subjenis *Blastocystis* yang berkaitan dengan microbiota usus. Subjenis *Blastocystis* dikenal pasti dengan menggunakan tindak balas berantai polimeras (PCR) dan microbiota najis dianalisis dengan menyasarkan pada kawasan V4 gen ribosomal 16S bakteria. Hasil kajian mendapati bahawa prevalens *Blastocystis* adalah lebih tinggi dalam kalangan T2DM (25.49%) berbanding bukan-DM (17.82%). Subjenis yang paling biasa dalam populasi keseluruhan adalah ST3, diikuti oleh ST1 dan ST2. Perubahan adalah signifikan dalam komposisi microbiota usus ditemui antara T2DM dan bukan-DM dengan menunjukkan kumpulan bukan-DM mempunyai kepelbagaian alfa yang lebih tinggi berdasarkan kekayaan spesies dan indeks kepelbagaian. Selain itu, kehadiran *Blastocystis* menunjukkan signifikan berkaitan dengan peningkatan kepelbagaian alfa dalam kedua-dua kumpulan T2DM dan bukan-DM. Pada peringkat filum, kumpulan T2DM menunjukkan peningkatan yang ketara dalam Bacteroidetes dan penurunan yang ketara dalam Actinobacteria dengan kehadiran *Blastocystis* berbanding dengan kumpulan *Blastocystis*-negatif. Selain itu, analisis profil genus juga mendedahkan bahawa subjenis *Blastocystis* yang berbeza menunjukkan kepelbagaian jumlah genus seperti *Prevotella*, *Bifidobacterium*, *Blautia* dan *Megamonas*. Secara khususnya, kekayaan filum yang bukan dominan seperti Lentisphaerae dan Tenericutes dapat dilihat secara signifikan dalam *Blastocystis* ST1 dan ST3 berbanding subjenis yang lain. Menariknya, kajian ini juga mengaitkan hubungan antara sampel yang sangat terhad iaitu jangkitan daripada *Blastocystis* ST7 dengan peningkatan bakteria patogen seperti *Escherichia-Shigella* dalam individu dengan T2DM. Penemuan ini mencadangkan bahawa subjenis *Blastocystis* yang berbeza mungkin telah menyumbang kepada microbiota usus yang lebih sihat atau berpotensi menyebabkan dysbiosis. Walau bagaimanapun, analisis lanjutan pada tahap subjenis (ST) adalah perlu untuk menjelaskan peranan khusus subjenis *Blastocystis* dalam kesihatan usus, kerana mereka mungkin menunjukkan ciri-ciri komensal dan patogenik.

ABSTRACT

The influence of the anaerobic intestinal protozoan *Blastocystis* on human gut health remains poorly understood, particularly in type 2 diabetes mellitus (T2DM). A high prevalence of *Blastocystis* infection has been reported in T2DM patients, suggesting a potential link with gut microbiota. However, this association is not well documented in clinical settings. Hence, a comparative cross-sectional study was conducted involving 203 participants, including both T2DM patients and non-diabetic (NonDM) individuals, to evaluate the prevalence of *Blastocystis* subtypes associated with gut microbiota. *Blastocystis* subtypes were identified using polymerase chain reaction (PCR) and the faecal microbiome was analysed by targeting the V4 region of the bacterial 16S ribosomal gene. Our findings revealed that the prevalence of *Blastocystis* was higher in T2DM (25.49%) compared to NonDM (17.82%). The most common subtypes (STs) in the overall population were ST3, followed by ST1 and ST2. Notably, a significant change in the composition of gut microbiota was discovered between T2DM and NonDM with the NonDM group exhibiting higher alpha diversity based on species richness and diversity index. Furthermore, it was discovered that in both T2DM and NonDM, the presence of *Blastocystis* was significantly linked to increased alpha diversity. At the phylum level, the T2DM group showed a notable increase in Bacteroidetes and a marked decrease in Actinobacteria in the presence of *Blastocystis* compared with the negative *Blastocystis* group. Additionally, our genus profile analysis revealed that different *Blastocystis* subtypes exhibited a significant abundance of genera such as *Bacteroides*, *Prevotella* 9, *Bifidobacterium*, *Blautia* and *Megamonas*. Specifically, the abundance of Lentisphaerae and Tenericutes in less dominant phyla was significantly increased in *Blastocystis* ST1 and ST3 compared to other STs. Interestingly, a limited sample infected by *Blastocystis* ST7 was associated with an increase in pathogenic bacteria like *Escherichia-Shigella* in individuals with T2DM. These findings suggested that different *Blastocystis* subtypes may have contributed to a healthier gut microbiota or potentially led to dysbiosis. However, advanced analysis at the subtype (ST) level is necessary to elucidate the specific role of *Blastocystis* subtypes in gut health, as they may exhibit both commensal and pathogenic characteristics.

المُلخَص

على صحة الأمعاء البشرية لا يزال غير مفهوم تمامًا، خاصة *Blastocystis* تأثير البروتوزوا المعوية اللاهوائية في مرضى *Blastocystis* تم الإبلاغ عن انتشار مرتفع لعدوى (T2DM) في مرض السكري من النوع 2 مما يشير إلى رابط محتمل مع ميكروبيوتا الأمعاء. ومع ذلك، فإن هذه العلاقة غير موثقة بشكل جيد في T2DM، البيانات السريرية. ومن ثم، تم إجراء دراسة مقطعية مقارنة شملت 203 مشاركًا، بما في ذلك مرضى المرتبطة بميكروبيوتا *Blastocystis* لتقييم انتشار الأنماط الفرعية لـ (NonDM) وأفراد غير مصابين بالسكري وتم تحليل (PCR) الفرعية باستخدام تفاعل البوليميراز المتسلسل *Blastocystis* الأمعاء. تم تحديد أنماط للبكتيريا. كشفت نتائجنا أن انتشار S من الجين الريبي V4 16 الميكروبيوم البرازي من خلال استهداف منطقة كانت الأنماط الفرعية (17.82%) NonDM مقارنة بـ (25.49%) T2DM كان أعلى في *Blastocystis* ومن الملاحظ أن هناك تغييرًا كبيرًا في ST2 و ST1 تليها، ST3 في السكان الإجمالي هي (STs) الأكثر شيوعًا تنوعًا أعلى بناءً على NonDM حيث أظهر مجموعة NonDM و T2DM تركيب ميكروبيوتا الأمعاء بين كانت وجود NonDM و T2DM ثراء الأنواع ومؤشر التنوع. علاوة على ذلك، تم اكتشاف أنه في كل من زيادة T2DM مرتبطًا بشكل كبير بزيادة التنوع الألفا. على مستوى الفصيلة، أظهرت مجموعة *Blastocystis* مقارنة *Blastocystis* في وجود *Actinobacteria* وانخفاضًا ملحوظًا في *Bacteroidetes* ملحوظة في السلبية. بالإضافة إلى ذلك، كشفت تحليل ملف الأنواع لدينا أن الأنماط الفرعية المختلفة *Blastocystis* بمجموعة 9، *Bacteroides*، *Prevotella* أظهرت وفرة ملحوظة من الأجناس مثل *Blastocystis* لـ *Lentisphaerae* على وجه الخصوص، كانت وفرة *Bifidobacterium*، *Blautia* و *Megamonas*. كانت وفرة *Blastocystis* ST1 في الفصائل الأقل هيمنة زادت بشكل ملحوظ في الأنماط الفرعية **Tenericutes** و كانت *Blastocystis* ST7 الأخرى. ومن المثير للاهتمام، أن عينة محدودة مصابة بـ ST مقارنة بأنماط ST3 T2DM. في الأفراد المصابين بـ *Escherichia-Shigella* مرتبطة بزيادة في البكتيريا المسببة للأمراض مثل قد ساهمت في ميكروبيوتا أمعاء أكثر صحة *Blastocystis* تشير هذه النتائج إلى أن الأنماط الفرعية المختلفة لـ ضروري (ST) أو قد أدت إلى اختلال التوازن الميكروبي. ومع ذلك، فإن التحليل المتقدم عند مستوى النمط الفرعي في صحة الأمعاء، حيث قد تظهر خصائص متعايشة *Blastocystis* لتوضيح الدور المحدد للأنماط الفرعية لـ "ومسببة للأمراض".

TABLE OF CONTENTS

CONTENT	PAGE
AUTHOR DECLARATION AND COPYRIGHT	i
ACKNOWLEDGEMENTS	ii
ABSTRAK	iii
ABSTRACT	iv
المُلَخَّص	v
TABLE OF CONTENTS	vi
LIST OF TABLES	viii
LIST OF FIGURES	xi
LIST OF APPENDICES	xiii
LIST OF ABBREVIATIONS	xiv
 CHAPTER 1	 1
1.1 Introduction	1
1.2 Background of the Study	1
1.3 Problem Statement	9
1.4 Justification of the Study	10
1.5 Research Questions	14
1.6 Objectives	14
1.6.1 General Objective	14
1.6.2 Specific Objectives	14
1.7 Hypotheses	15
1.8 The Significance of the Study	16
1.9 Scope of Study	17
1.10 Conceptual Framework	18
1.11 Operational Definition	20
1.12 Conclusion	21
 CHAPTER 2	 22
2.1 Introduction	22
2.2 <i>Blastocystis</i>	22
2.2.1 Biology	28
2.2.2 Morphology	29
2.2.3 Life cycle and transmission	29
2.2.4 <i>Blastocystis</i> is one of the Intestinal parasite infections (IPIs)	31
2.2.5 Genetic diversity and <i>Blastocystis</i> pathogenicity	34
2.2.6 Prevalence of <i>Blastocystis</i> infection in diabetes diseases	42
2.2.7 Laboratory Diagnosis for <i>Blastocystis</i>	46
2.2.7.1 Microscopy	46
2.2.7.2 In vitro cultivation	47
2.2.7.3 Conventional Polymerase Chain Reaction (PCR) and Real-time Polymerase Chain Reaction (Rt-PCR)	49
2.2.7.4 Next gene sequencing (NGS) – <i>Blastocystis</i>	53

2.3 Diabetes disease	54
2.3.1 Development and Pathogenesis of T2DM.....	56
2.3.2 Pro-Inflammatory Cytokines: IL-1 and IL-6 in T2DM.....	58
2.3.3 Diagnosis and Management of T2DM	61
2.4 Human Gut Microbiota.....	63
2.4.1 Development of Gut Microbiota	64
2.4.2 Gut Microbiota and T2DM	67
2.4.3 Association of <i>Blastocystis</i> in the gut microbiota composition	71
2.4.4 Next-Generation Sequencing (NGS), 16S rDNA Sequencing.....	80
2.5 Conclusion	81
CHAPTER 3	82
3.1 Introduction	82
3.2 Study design	82
3.3 Study site and rationale	83
3.4 Study population.....	84
3.5 Sample size calculation	86
3.6 Study sampling	87
3.7 Methodology flow chart	88
3.8 Study procedure.....	89
3.8.1 Data and samples collection.....	89
3.8.2 Stool sample processing: Molecular techniques.....	90
3.8.2.1 Detection of <i>Blastocystis</i>	90
a) DNA extraction.....	90
b) DNA Quantification	91
c) PCR Amplification Using Conventional PCR Method	91
d) PCR Product Analysis Using Gel Electrophoresis.....	92
e) DNA sequencing	93
f) Identification of <i>Blastocystis</i> Subtypes and Alleles.....	93
3.8.2.2 Detection of Microbiota: Metagenomics of Gut Microbiota	94
a) Genomic extraction	94
b) DNA Quality control and Library Construction for Next Gene Sequencing (NGS)	95
c) Bioinformatic analysis	97
3.8.2.3 Pro-inflammatory Marker Detection: Solid Phase Sandwich ELISA (Enzyme-Linked Immunosorbent Assay) for IL-6 and IL-1 β Quantification	99
3.9 Statistical analysis	100
3.10 Ethics and protection of subjects.....	102
3.10.1 Approval of Institutional Review Board	102
3.10.2 Patient's information Sheet and Consent	102
3.10.3 Management of sample collection during the COVID pandemic	103
3.11 Conclusion.....	103
CHAPTER 4	104

4.1 Introduction	104
4.2 Sociodemographic characteristics in T2DM patients and NonDM.....	104
4.3 Prevalence rates of <i>Blastocystis</i> sp. infection by Polymerase Chain Reaction PCR	106
4.4 Association of <i>Blastocystis</i> detected by PCR with Gastrointestinal symptoms.....	110
4.4.1 Association of <i>Blastocystis</i> subtypes with gastrointestinal symptoms ..	112
4.5 Gut Microbiota Analysis	114
4.5.1 Diversity analysis	114
4.5.1.1 Alpha Diversity	118
4.5.1.2 Beta Diversity	121
4.5.2 Gut Microbiota Composition.....	124
4.5.2.1 Comparison of the Gut Composition between T2DM and NonDM	127
4.5.2.2 Gut Microbiota Composition in T2DM when compared to NonDM by <i>Blastocystis</i> infection.....	131
4.5.2.3 Gut Microbiota Composition by <i>Blastocystis</i> infection subtypes among T2DM and NonDM.....	137
4.6 Association of <i>Blastocystis</i> subtypes with IL-6 and IL1- β	142
4.7 Correlation analysis of <i>Blastocystis</i> infection with gut microbiota and pro-inflammation markers (IL-6 and IL1- β)	143
4.8 Conclusion	145
CHAPTER 5	146
5.1 Introduction	146
5.2 <i>Blastocystis</i> subtypes prevalence in Type 2 Diabetes Mellitus (T2DM) and non-diabetic (NonDM).....	146
5.3 Association of <i>Blastocystis</i> subtypes with gastrointestinal symptoms.....	151
5.4 Gut Microbiota Composition in T2DM Compared to NonDM.....	154
5.5 Association between <i>Blastocystis</i> subtypes and the gut microbiota and its correlation with IL-6 and IL1- β	162
CHAPTER 6	174
6.1 Recommendation of the study	174
6.2 Strengths and Limitations of the Study.....	176
6.3 Conclusion.....	178
REFERENCES	181
APPENDICES	213

LIST OF TABLES

Tables

Page

Table 2.1:	Characteristics to reclassify <i>B. hominis</i> from fungi to protozoa	24
Table 2.2:	Classification of <i>Blastocystis</i>	27
Table 2.3:	Possible subtype contribution to <i>Blastocystis</i> pathogenicity	37
Table 2.4:	Studies on the prevalence of <i>Blastocystis</i> in Diabetic patients and non-diabetic group	45
Table 2.5	Gut Composition in T2DM and NonDM in clinical studies using 16S rDNA sequencing	69-70
Table 2.6	Studies on Association of <i>Blastocystis</i> Colonisation in Gut composition infected in Humans and Mices	76-79
Table 3.1:	Inclusion and exclusion criteria	85
Table 3.2:	RD5 and BhRDr primers	91
Table 3.3:	V4 Region profile of Bacterial 16 rRNA Amplification	94
Table 4.1:	The Characteristics of Study Participants in T2DM and NonDM Groups (n=203)	105
Table 4.2:	Gastrointestinal Symptoms Observed in <i>Blastocystis</i> Positive (n=44) Individuals and <i>Blastocystis</i> Negative (n=159)	111
Table 4.3:	The Gastrointestinal Symptoms relevant to <i>Blastocystis</i> Subtypes Detected, n=44	113
Table 4.4:	Bacterial Alpha Diversity in T2DM and NonDM, n=100	118
Table 4.5:	Bacterial Alpha Diversity in T2DM and NonDM according to <i>Blastocystis</i> positive and <i>Blastocystis</i> negative group, n=100	119
Table 4.6:	Bacterial Beta Diversity in T2DM and NonDM according to <i>Blastocystis</i> positive and <i>Blastocystis</i> negative group, n=100	122
Table 4.7:	Top 10 Bacteria Phyla and Genera in T2DM and NonDM groups arranged by abundance, n=100	128
Table 4.8:	Comparisons of Phyla and Genera abundance with and without <i>Blastocystis</i> infection in T2DM and NonDM groups, n=100	133
Table 4.9:	Association of Gut Microbiota Composition between <i>Blastocystis</i> subtypes (ST1-ST3) and non-infected	138-139

Table 4.10: Association of Gut Microbiota Composition between 140-
Blastocystis subtypes (ST4-ST7) and non-infected 141

Table 4.11: Association between *Blastocystis* subtypes and IL-6 and IL1- β 142

UNIVERSITI SAINS ISLAM MALAYSIA
جامعة العلوم الإسلامية
ISLAMIC SCIENCE UNIVERSITY OF MALAYSIA

LIST OF FIGURES

Figures	Page
Figure 1.1: Conceptual Framework showing the Infection of <i>Blastocystis</i> in the Type-2 Diabetes Mellitus (T2DM) and Non-Diabetic Group (NonDM) that Associated with Gut Microbiota by using Polymerase Chain Reaction (PCR), Next Gene Sequencing (NGS) and ELISA	18
Figure 2.1: Concept map summarising the Pathogenicity and Commensal nature of <i>Blastocystis</i> infection based on the literature review	41
Figure 3.1: Flowchart of Convenient Sampling	87
Figure 3.2: Methodology Flowchart	88
Figure 3.3: Flowchart for 16S Amplicon Library Preparation Workflow	94
Figure 3.4: 16S Amplicon Sequencing Analysis Pipeline	97
Figure 4.1: Partial SSU rRNA Gene of <i>Blastocystis</i> in Diabetic Patients were electrophoresed on 1.5% Agarose Gel. All samples amplified 600 bp	108
Figure 4.2: Partial SSU rRNA gene of <i>Blastocystis</i> sp. in non-Diabetic individuals were electrophoresed on 1.5% Agarose Gel. All samples amplified 600 bp amplicon	109
Figure 4.3: Individual Rarefaction Curve within samples in T2DM and NonDM	116
Figure 4.4: Group Rarefaction Curve in T2DM and NonDM	117
Figure 4.5: Alpha diversity differences in bacterial richness (Observed ASV and Chao 1) and bacterial diversity (Fisher, Shannon's diversity and Simpson's index) between T2DM <i>Blastocystis</i> positive, T2DM <i>Blastocystis</i> negative, NonDM <i>Blastocystis</i> positive and NonDM <i>Blastocystis</i> negative	120

Figure 4.6:	Beta diversity of <i>Blastocystis</i> -positive and <i>Blastocystis</i> -negative in T2DM and NonDM faecal samples visualised by PCoA plots of Bray-Curtis dissimilarities	123
Figure 4.7:	Plot Bar of Abundance at the Phylum Level between Study Participants	125
Figure 4.8:	Plot Bar of Abundance at the Genus Level between Study Participants	126
Figure 4.9:	Comparison of the Gut Composition between T2DM and NonDM at the top 10 Phylum Level	129
Figure 4.10:	Comparison of the Gut Composition between T2DM and NonDM at the top 10 Genus Level	130
Figure 4.11:	Comparison of the Gut Composition between <i>Blastocystis</i> Positive and <i>Blastocystis</i> Negative in T2DM and non-Diabetic Groups at the Phylum Level	135
Figure 4.12:	Comparison of the Gut Composition between <i>Blastocystis</i> Positive and <i>Blastocystis</i> Negative in T2DM and non-Diabetic Groups at the Genus Level	136
Figure 4.13:	Heatmap showing Correlation of Bacterial Phyla and Genera with Clinical Characteristics in All Participants, n=100	144
Figure 5.1:	Concept map integrating the Commensal and Pathogenicity aspects of <i>Blastocystis</i> from various studies and current research findings	173

LIST OF APPENDICES

Appendices	Page
Appendix A: Sample Size Calculation	213
Appendix B: Poster invitation for research	214
Appendix C: Participant Information Sheet and Informed Consent Form	215-218
Appendix D: Questionnaire	219-221
Appendix E: Ethical Approval letter from USIM and UKM	222-223
Appendix F: Genomic DNA Quantification Report from Apical Scientific	224-225
Appendix G: 16S gene (V4) QC PCR result report from Apical Scientific	226

LIST OF ABBREVIATIONS

ASVs	Amplicon sequence variants
BCAAs	Branched-Chain Amino Acid
BMI	Body Mass Index
BP	Base-pair
COVID-19	Corona Virus Disease 2019
DESeq	Differential expression analysis for sequence count data
DSS	Dextran sulphate sodium
ELISA	Enzyme-Linked Immunosorbent Assay
FBS	Fasting Blood Sugar
FDR	False Discovery Rate
gDNA	Genomic Deoxyribonucleic Acid
GLP-1	Glucagon-like peptide 1
HbA1c	Haemoglobin A1c
IBD	Inflammatory bowel disease
IBS	Irritable bowel syndrome
IL1-β	Interleukin 1 β
IL6	Interleukin 6
IgA	Immunoglobulin A
IR	Insulin resistance
LPS	Lipopolysaccharide
MAPKs	Mitogen- activated protein kinases
PBMCs	Peripheral Blood Mononuclear Cells
NonDM	non-Diabetic Mellitus
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NGS	Next Generation sequencing
PCoA	Principal Coordinates Analysis
PCOS	Polycystic Ovary Syndrome
PCR	Polymerase Chain Reaction
PCR-QC	Polymerase Chain Reaction Quality Control
PGN	Peptidoglycans
rDNA	Ribosomal DNA
SCFA	Short-chain fatty acid
Sp.	Species
SPSS	Statistical Package for the Social Sciences
ST	Subtype
T2DM	Type- 2 Diabetes Mellitus
TNF-α	Tumour Necrosis Factor alpha